Brief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
16/10/2026 23:08
BRIEF-Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia Oct 16 (Reuters) - Viatris Inc. VTRS.O:
VIATRIS RECEIVES U.S. FDA APPROVAL FOR RYZUMVI® FOR THE TREATMENT OF PRESBYOPIA
VIATRIS - EXPLORING U.S. COMMERCIALIZATION PARTNER FOR RYZUMVI FOR PRESBYOPIA
Source text: ID:nPn8CYLk7a
Further company coverage: VTRS.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal